1. The role of hypofractionated radiotherapy for the definitive treatment of localized prostate cancer: early results of a randomized trial
- Author
-
Konstantina Boniou, Haidong Huang, Konstantinos Romanidis, Iason Nikolaos-Katsios, Aikaterini Amaniti, Qiang Li, Dimitris Giannakidis, Wolfgang Hohenforst-Schmidt, Aris Ioannidis, Konstantinos Sapalidis, Savvas Petanidis, Panagoula Oinkonomou, Charilaos Koulouris, Isaak Kesisoglou, Anastasios Vagionas, Sotirios Karatzoglou, Varbara Fyntanidou, Ioannis Tzitzikas, Paul Zarogoulidis, Zoi Aidoini, Christoforos Kosmidis, Ioannis Chrisogonidis, Athanasios Katsaounis, Elena Maragouli, Nikolaos V. Michalopoulos, Dimitris Dragoumis, Petros Alexidis, Konstantinos Drevelegas, and Konstantinos Hatzimouratidis
- Subjects
medicine.medical_specialty ,Hypofractionated Radiation Therapy ,business.industry ,hypofractionation ,medicine.medical_treatment ,Urology ,medicine.disease ,prostate cancer ,Acute toxicity ,law.invention ,Radiation therapy ,Prostate cancer ,medicine.anatomical_structure ,Oncology ,Randomized controlled trial ,law ,Prostate ,Toxicity ,early toxicity ,medicine ,Hormone therapy ,business ,Research Paper - Abstract
Background: Prostate cancer is considered to have a special biology which could affect the radiation therapy result based on the selected fractionation scheme. We present the preliminary results of a randomized trial comparing conventionally and hypofractionated radiation therapy for prostate cancer. Methods: Patients included in the study had localized prostate cancer (cT1c-T3bN0M0) and were randomly assigned to mild hypofractionated (72 Gy in 32 fractions, arm1) or conventionally fractionated (74 Gy in 37 fractions, arm2) radiation therapy treatment with Volumetric Arc Therapy technique. The treatment was delivered only to the prostate with or without the seminal vesicles according to physician's discretion and hormone therapy was optional according to the disease stage and comorbidities. Here we present the preliminary results of acute toxicity from the gastrointestinal (GI) and genitourinary (GU) system. Results: Between 2015 and 2016, 139 patients were enrolled. 67 patients were treated with conventional fractionation and 72 were treated with hypofractionation. Grade≥ 2 toxicity from GU and GI was observed in 23 and 21 patients (31,9% vs 31,3%, p=0,79) and 15 and 12 (20,8% vs 17,9%, p=0,6) for arm1 and arm2 respectively. No statistically significant differences were observed between arms in the incidence of early toxicity. There was no correlation observed between patient characteristics and toxicity from either GU or GI. Conclusions: Hypofractionated radiotherapy appears to be equally tolerated compared to conventional fractionation in the early setting. Longer follow up is needed to assess the late toxicity profile of the patients and any potential differences between the control and experimental arm.
- Published
- 2019